Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 5/2011

01-10-2011

Alternative Transplantation Sites for Pancreatic Islet Grafts

Authors: Elisa Cantarelli, Lorenzo Piemonti

Published in: Current Diabetes Reports | Issue 5/2011

Login to get access

Abstract

The liver is the current site of choice for pancreatic islet transplantation, even though it is far from being an ideal site because of immunologic, anatomic, and physiologic factors leading to a significant early graft loss. A huge amount of alternative sites have been used for islet transplantation in experimental animal models to provide improved engraftment and long-term survival minimizing surgical complications. The pancreas, gastric submucosa, genitourinary tract, muscle, omentum, bone marrow, kidney capsule, peritoneum, anterior eye chamber, testis, and thymus have been explored. Site-specific differences exist in term of islet engraftment, but few alternative sites have potential clinical translation and generally the evidence of a post-transplant islet function better than that reached after intraportal infusion is still lacking. This review discusses site-specific benefits and drawbacks taking into account immunologic, metabolic, and technical aspects to identify the ideal microenvironment for islet function and survival.
Literature
1.
Kemp CB et al. Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia. 1973;9(6):486–91.PubMedCrossRef
2.
Najarian JS et al. Total or near total pancreatectomy and islet autotransplantation for treatment of chronic pancreatitis. Ann Surg. 1980;192(4):526–42.PubMedCrossRef
3.
Sutherland DE et al. Transplantation of dispersed pancreatic islet tissue in humans: autografts and allografts. Diabetes. 1980;29 Suppl 1:31–44.PubMed
4.
Scharp DW et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes. 1990;39(4):515–8.PubMedCrossRef
5.
• Melzi R et al. Intrahepatic islet transplant in the mouse: functional and morphological characterization. Cell Transplant. 2008;17(12):1361–70. This study demonstrated that islet transplantation via the portal vein in the mouse model has similar features to human islet transplantation and should be used as a model to study not only engraftment but also mechanisms of immune suppression and tolerance.PubMedCrossRef
6.
Toyofuku A et al. Natural killer T-cells participate in rejection of islet allografts in the liver of mice. Diabetes. 2006;55(1):34–9.PubMedCrossRef
7.
Yasunami Y et al. Valpha14 NK T cell-triggered IFN-gamma production by Gr-1 + CD11b + cells mediates early graft loss of syngeneic transplanted islets. J Exp Med. 2005;202(7):913–8.PubMedCrossRef
8.
Carlsson PO et al. Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. Diabetes. 2001;50(3):489–95.PubMedCrossRef
9.
Korsgren O et al. Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia. 2008;51(2):227–32.PubMedCrossRef
10.
•• Eriksson O et al. Positron emission tomography in clinical islet transplantation. Am J Transplant. 2009;9(12):2816–24. This study demonstrated that positron emission tomography combined with CT allows real-time quantitative and qualitative measurements of islet kinetics and distribution during the first hours after islet infusion in the portal vein.PubMedCrossRef
11.
Barshes NR et al. Transaminitis after pancreatic islet transplantation. J Am Coll Surg. 2005;200(3):353–61.PubMedCrossRef
12.
Rafael E et al. Changes in liver enzymes after clinical islet transplantation. Transplantation. 2003;76(9):1280–4.PubMedCrossRef
13.
• Sakata N et al. MRI assessment of ischemic liver after intraportal islet transplantation. Transplantation. 2009;87(6):825–30. This paper showed that MRI is useful for the detection and quantification of ischemic, necrotic and apoptotic areas in ex vivo murine livers after islet transplantation.PubMedCrossRef
14.
Venturini M et al. Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in type 1 diabetes: the role of US. Radiology. 2005;234(2):617–24.PubMedCrossRef
15.
Ferguson J, Scothorne RJ, Johnston ID. Proceedings: the survival of transplanted isolated pancreatic islets in the omentum and testis. Br J Surg. 1973;60(11):907.PubMed
16.
Kim HI et al. Comparison of four pancreatic islet implantation sites. J Korean Med Sci. 2010;25(2):203–10.PubMedCrossRef
17.
Pileggi A et al. Impact of pancreatic cold preservation on rat islet recovery and function. Transplantation. 2009;87(10):1442–50.PubMedCrossRef
18.
Paraskevas S et al. Activation and expression of ERK, JNK, and p38 MAP-kinases in isolated islets of Langerhans: implications for cultured islet survival. FEBS Lett. 1999;455(3):203–8.PubMedCrossRef
19.
Abdelli S et al. Intracellular stress signaling pathways activated during human islet preparation and following acute cytokine exposure. Diabetes. 2004;53(11):2815–23.PubMedCrossRef
20.
Sklavos MM et al. Redox modulation protects islets from transplant-related injury. Diabetes. 2010;59(7):1731–8.PubMedCrossRef
21.
Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol. 2005;77(5):587–97.PubMedCrossRef
22.
Bennet W et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes. 1999;48(10):1907–14.PubMedCrossRef
23.
Ozmen L et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes. 2002;51(6):1779–84.PubMedCrossRef
24.
•• Moberg L et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 2002;360(9350):2039–45.PubMedCrossRef
25.
Johansson H et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes. 2005;54(6):1755–62.PubMedCrossRef
26.
Yin D et al. Liver ischemia contributes to early islet failure following intraportal transplantation: benefits of liver ischemic-preconditioning. Am J Transplant. 2006;6(1):60–8.PubMedCrossRef
27.
Bottino R et al. Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation. Diabetes. 1998;47(3):316–23.PubMedCrossRef
28.
Moberg L, Korsgren O, Nilsson B. Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood. Clin Exp Immunol. 2005;142(1):125–31.PubMedCrossRef
29.
Bertuzzi F et al. Tissue factor and CCL2/monocyte chemoattractant protein-1 released by human islets affect islet engraftment in type 1 diabetic recipients. J Clin Endocrinol Metab. 2004;89(11):5724–8.PubMedCrossRef
30.
Piemonti L et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes. 2002;51(1):55–65.PubMedCrossRef
31.
Johansson U et al. Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. Biochem Biophys Res Commun. 2003;308(3):474–9.PubMedCrossRef
32.
• Matsuoka N et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest. 2010;120(3):735–43. The present study investigated in the mouse model the mechanisms involved in the early loss of transplanted islets focusing the attention on HMGB1 as a mediator of cell damage. These results demonstrated that HMGB1 is released from intraliver-infused islets and stimulates the production of inflammatory cytokines, which in turn accelerates graft injury.PubMedCrossRef
33.
Tiedge M et al. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes. 1997;46(11):1733–42.PubMedCrossRef
34.
Robertson RP, Harmon JS. Pancreatic islet beta-cell and oxidative stress: the importance of glutathione peroxidase. FEBS Lett. 2007;581(19):3743–8.PubMedCrossRef
35.
Scapini P et al. The neutrophil as a cellular source of chemokines. Immunol Rev. 2000;177:195–203.PubMedCrossRef
36.
Ballian N, Brunicardi FC. Islet vasculature as a regulator of endocrine pancreas function. World J Surg. 2007;31(4):705–14.PubMedCrossRef
37.
Jansson L, Carlsson PO. Graft vascular function after transplantation of pancreatic islets. Diabetologia. 2002;45(6):749–63.PubMedCrossRef
38.
Brissova M et al. Intraislet endothelial cells contribute to revascularization of transplanted pancreatic islets. Diabetes. 2004;53(5):1318–25.PubMedCrossRef
39.
Carlsson PO, Palm F, Mattsson G. Low revascularization of experimentally transplanted human pancreatic islets. J Clin Endocrinol Metab. 2002;87(12):5418–23.PubMedCrossRef
40.
Lau J et al. Implantation site-dependent dysfunction of transplanted pancreatic islets. Diabetes. 2007;56(6):1544–50.PubMedCrossRef
41.
Nyqvist D et al. Donor islet endothelial cells participate in formation of functional vessels within pancreatic islet grafts. Diabetes. 2005;54(8):2287–93.PubMedCrossRef
42.
Vajkoczy P et al. Histogenesis and ultrastructure of pancreatic islet graft microvasculature. Evidence for graft revascularization by endothelial cells of host origin. Am J Pathol. 1995;146(6):1397–405.PubMed
43.
Desai NM et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Transplantation. 2003;76(11):1623–5.PubMedCrossRef
44.
Shapiro AM et al. The portal immunosuppressive storm: relevance to islet transplantation? Ther Drug Monit. 2005;27(1):35–7.PubMedCrossRef
45.
Cantaluppi V et al. Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. Am J Transplant. 2006;6(11):2601–11.PubMedCrossRef
46.
Zhang N et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes. 2006;55(9):2429–36.PubMedCrossRef
47.
Zahr E et al. Rapamycin impairs in vivo proliferation of islet beta-cells. Transplantation. 2007;84(12):1576–83.PubMedCrossRef
48.
Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest. 2007;117(9):2553–61.PubMedCrossRef
49.
Leitao CB et al. Lipotoxicity and decreased islet graft survival. Diabetes Care. 2010;33(3):658–60.PubMedCrossRef
50.
Dombrowski F, Mathieu C, Evert M. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in autoimmune diabetic BB/Pfd rats. Cancer Res. 2006;66(3):1833–43.PubMedCrossRef
51.
Markmann JF et al. Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes. 2003;52(7):1591–4.PubMedCrossRef
52.
Bhargava R et al. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes. 2004;53(5):1311–7.PubMedCrossRef
53.
Stagner JI, Rilo HL, White KK. The pancreas as an islet transplantation site. Confirmation in a syngeneic rodent and canine autotransplant model. JOP. 2007;8(5):628–36.PubMed
54.
Carlsson PO et al. Measurements of oxygen tension in native and transplanted rat pancreatic islets. Diabetes. 1998;47(7):1027–32.PubMedCrossRef
55.
Caiazzo R et al. Evaluation of alternative sites for islet transplantation in the minipig: interest and limits of the gastric submucosa. Transplant Proc. 2007;39(8):2620–3.PubMedCrossRef
56.
Wszola M et al. TransEndoscopic Gastric SubMucosa Islet Transplantation (eGSM-ITx) in pigs with streptozotocine induced diabetes - technical aspects of the procedure - preliminary report. Ann Transplant. 2009;14(2):45–50.PubMed
57.
Echeverri GJ et al. Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. Am J Transplant. 2009;9(11):2485–96.PubMedCrossRef
58.
Burgos FJ et al. Pancreas islet transplantation in the genitourinary tract associated with renal transplantation: an experimental study. Transplant Proc. 2006;38(8):2585–7.PubMedCrossRef
59.
Stegall MD et al. Evidence of recurrent autoimmunity in human allogeneic islet transplantation. Transplantation. 1996;61(8):1272–4.PubMedCrossRef
60.
Weber CJ et al. Tissue culture preservation and intramuscular transplantation of pancreatic islets. Surgery. 1978;84(1):166–74.PubMed
61.
Rafael E et al. Intramuscular autotransplantation of pancreatic islets in a 7-year-old child: a 2-year follow-up. Am J Transplant. 2008;8(2):458–62.PubMedCrossRef
62.
Svensson J et al. High Vascular Density and Oxygenation of Pancreatic Islets Transplanted in Clusters into Striated Muscle. Cell Transplant. 2010 Nov 5. [Epub ahead of print]
63.
Christoffersson G et al. Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets. Diabetes. 2010;59(10):2569–78.PubMedCrossRef
64.
Lund T et al. Sustained reversal of diabetes following islet transplantation to striated musculature in the rat. J Surg Res. 2010;160(1):145–54.PubMedCrossRef
65.
Fritschy WM et al. The efficacy of intraperitoneal pancreatic islet isografts in the reversal of diabetes in rats. Transplantation. 1991;52(5):777–83.PubMedCrossRef
66.
Lorenz D et al. Transplantation of isologous islets of Langerhans in diabetic rats. Acta Diabetol Lat. 1975;12(1):30–40.PubMedCrossRef
67.
Kobayashi T et al. Indefinite islet protection from autoimmune destruction in nonobese diabetic mice by agarose microencapsulation without immunosuppression. Transplantation. 2003;75(5):619–25.PubMedCrossRef
68.
Wahoff DC et al. Intraperitoneal transplantation of microencapsulated canine islet allografts with short-term, low-dose cyclosporine for treatment of pancreatectomy-induced diabetes in dogs. Transplant Proc. 1994;26(2):804.PubMed
69.
Qi M et al. A recommended laparoscopic procedure for implantation of microcapsules in the peritoneal cavity of non-human primates. J Surg Res. 2011;168(1):e117–23.PubMedCrossRef
70.
Elliott RB et al. Intraperitoneal alginate-encapsulated neonatal porcine islets in a placebo-controlled study with 16 diabetic cynomolgus primates. Transplant Proc. 2005;37(8):3505–8.PubMedCrossRef
71.
Calafiore R et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care. 2006;29(1):137–8.PubMedCrossRef
72.
al-Abdullah IH et al. Site for unpurified islet transplantation is an important parameter for determination of the outcome of graft survival and function. Cell Transplant. 1995;4(3):297–305.PubMedCrossRef
73.
Kin T, Korbutt GS, Rajotte RV. Survival and metabolic function of syngeneic rat islet grafts transplanted in the omental pouch. Am J Transplant. 2003;3(3):281–5.PubMedCrossRef
74.
Ao Z et al. Survival and function of purified islets in the omental pouch site of outbred dogs. Transplantation. 1993;56(3):524–9.PubMedCrossRef
75.
Gustavson SM et al. Islet auto-transplantation into an omental or splenic site results in a normal beta cell but abnormal alpha cell response to mild non-insulin-induced hypoglycemia. Am J Transplant. 2005;5(10):2368–77.PubMedCrossRef
76.
Berman DM et al. Long-term survival of nonhuman primate islets implanted in an omental pouch on a biodegradable scaffold. Am J Transplant. 2009;9(1):91–104.PubMedCrossRef
77.
Litbarg NO et al. Activated omentum becomes rich in factors that promote healing and tissue regeneration. Cell Tissue Res. 2007;328(3):487–97.PubMedCrossRef
78.
Ferguson J, Scothorne RJ. Extended survival of pancreatic islet allografts in the testis of guinea-pigs. J Anat. 1977;124(Pt 1):1–8.PubMed
79.
•• Cantarelli E et al. Bone marrow as an alternative site for islet transplantation. Blood. 2009;114(20):4566–74. This paper demonstrated both the efficacy and safety of BM as an alternative site for islet implantation in the mouse model.PubMedCrossRef
80.
Salazar-Banuelos A et al. Pancreatic islet transplantation into the bone marrow of the rat. Am J Surg. 2008;195(5):674–8. discussion 678.PubMedCrossRef
81.
Frassoni F et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008;9(9):831–9.PubMedCrossRef
82.
Szot GL, Koudria P, Bluestone JA. Transplantation of pancreatic islets into the kidney capsule of diabetic mice. J Vis Exp. 2007;9:404.PubMed
83.
Carlsson PO et al. Chronically decreased oxygen tension in rat pancreatic islets transplanted under the kidney capsule. Transplantation. 2000;69(5):761–6.PubMedCrossRef
84.
van Suylichem PT et al. Rat islet isograft function. Effect of graft volume and transplantation site. Transplantation. 1994;57(7):1010–7.PubMed
85.
Song HJ et al. Prolongation of islet graft survival using concomitant transplantation of islets and vascular endothelial cells in diabetic rats. Transplant Proc. 2010;42(7):2662–5.PubMedCrossRef
86.
Rackham CL et al. Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia. 2011;54(5):1127–35.PubMedCrossRef
87.
Sordi V et al. Mesenchymal cells appearing in pancreatic tissue culture are bone marrow-derived stem cells with the capacity to improve transplanted islet function. Stem Cells. 2010;28(1):140–51.PubMed
88.
Sakata N et al. Bone marrow cell cotransplantation with islets improves their vascularization and function. Transplantation. 2010;89(6):686–93.PubMedCrossRef
89.
Melzi R et al. Co-graft of allogeneic immune regulatory neural stem cells (NPC) and pancreatic islets mediates tolerance, while inducing NPC-derived tumors in mice. PLoS One. 2010;5(4):e10357.PubMedCrossRef
90.
Dufour JM et al. Comparison of successful and unsuccessful islet/Sertoli cell cotransplant grafts in streptozotocin-induced diabetic mice. Cell Transplant. 2008;16(10):1029–38.PubMedCrossRef
91.
Adeghate E, Donath T. Morphological findings in long-term pancreatic tissue transplants in the anterior eye chamber of rats. Pancreas. 1990;5(3):298–305.PubMedCrossRef
92.
• Speier S et al. Noninvasive in vivo imaging of pancreatic islet cell biology. Nat Med. 2008;14(5):574–8. This paper validated a noninvasive in vivo fluorescence imaging method to study islet revascularization and composition and β-cell function and death at cellular resolution.PubMedCrossRef
93.
Perez VL et al. The anterior chamber of the eye as a clinical transplantation site for the treatment of diabetes: a study in a baboon model of diabetes. Diabetologia. 2011;54(5):1121–6.PubMedCrossRef
94.
•• Bellin MD et al. Similar islet function in islet allotransplant and autotransplant recipients, despite lower islet mass in autotransplants. Transplantation. 2011;91(3):367–72. This study compared islet function between allo- and autoislet transplant recipients at a similar time post-infusion and showed a better preservation of islet mass in the autograft setting due to the lack of autoimmunity, alloimmunity, and immunosuppressive drug toxicity.PubMedCrossRef
95.
• Vendrame F et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010;59(4):947–57. This study demonstrated that recurrent islet autoimmunity, measured both as autoantibodies and autoantigen-specific CD4 T cells, explained the hyperglycemia and loss of insulin secretion observed in three immunosuppressed simultaneous pancreas-kidney transplant recipients in the absence of rejection.PubMedCrossRef
96.
Bosi E et al. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes. 2001;50(11):2464–71.PubMedCrossRef
97.
• Roelen DL et al. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clin Exp Immunol. 2009;156(1):141–8. This observational study analyzed the influence of different immunosuppression therapies on autoreactive and alloreactive T-cell patterns and transplant outcome demonstrating that graft function correlates negatively with pretransplant cellular autoreactivity and is associated with the applied immunosuppressive regimen.PubMedCrossRef
98.
Jaeger C et al. Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation. Exp Clin Endocrinol Diabetes. 2000;108(5):328–33.PubMedCrossRef
99.
Braghi S et al. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes. 2000;49(2):218–24.PubMedCrossRef
100.
Roep BO et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes. 1999;48(3):484–90.PubMedCrossRef
101.
Huurman VA et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One. 2008;3(6):e2435.PubMedCrossRef
102.
Palmer JP et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes. 2004;53(1):250–64.PubMedCrossRef
103.
Pinkse GG et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A. 2005;102(51):18425–30.PubMedCrossRef
104.
Griffith TS et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270(5239):1189–92.PubMedCrossRef
105.
Bellgrau D et al. A role for CD95 ligand in preventing graft rejection. Nature. 1995;377(6550):630–2.PubMedCrossRef
106.
Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 1998;282(5394):1714–7.PubMedCrossRef
107.
Wilbanks GA, Mammolenti M, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol. 1992;22(1):165–73.PubMedCrossRef
108.
Margolis RN, Holup JJ, Selawry HP. Effects of intratesticular islet transplantation on hepatic glycogen metabolism in the rat. Diabetes Res Clin Pract. 1986;2(5):291–9.PubMedCrossRef
109.
Dai Z et al. Impaired recall of CD8 memory T cells in immunologically privileged tissue. J Immunol. 2005;174(3):1165–70.PubMed
110.
Ar'Rajab A et al. Immune privilege of the testis for islet xenotransplantation (rat to mouse). Cell Transplant. 1994;3(6):493–8.PubMed
111.
Nasr IW et al. Testicular immune privilege promotes transplantation tolerance by altering the balance between memory and regulatory T cells. J Immunol. 2005;174(10):6161–8.PubMed
112.
Gores PF et al. Long-term survival of intratesticular porcine islets in nonimmunosuppressed beagles. Transplantation. 2003;75(5):613–8.PubMedCrossRef
113.
Valdes-Gonzalez RA et al. Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: a 4-year study. Eur J Endocrinol. 2005;153(3):419–27.PubMedCrossRef
114.
Posselt AM et al. Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science. 1990;249(4974):1293–5.PubMedCrossRef
115.
Rayat GR et al. Survival and function of syngeneic rat islet grafts placed within the thymus versus under the kidney capsule. Cell Transplant. 1997;6(6):597–602.PubMedCrossRef
116.
Watt PC et al. Successful engraftment of autologous and allogeneic islets into the porcine thymus. J Surg Res. 1994;56(4):367–71.PubMedCrossRef
117.
Ludwig B et al. A novel device for islet transplantation providing immune protection and oxygen supply. Horm Metab Res. 2010;42(13):918–22.PubMedCrossRef
118.
Barnett BP et al. Fluorocapsules for improved function, immunoprotection, and visualization of cellular therapeutics with MR, US, and CT imaging. Radiology. 2011;258(1):182–91.PubMedCrossRef
119.
Stiegler P et al. Creation of a prevascularized site for cell transplantation in rats. Xenotransplantation. 2010;17(5):379–90.PubMedCrossRef
120.
Song C et al. Polyglycolic Acid-islet grafts improve blood glucose and insulin concentrations in rats with induced diabetes. Transplant Proc. 2009;41(5):1789–93.PubMedCrossRef
121.
Kin T et al. The use of an approved biodegradable polymer scaffold as a solid support system for improvement of islet engraftment. Artif Organs. 2008;32(12):990–3.PubMedCrossRef
Metadata
Title
Alternative Transplantation Sites for Pancreatic Islet Grafts
Authors
Elisa Cantarelli
Lorenzo Piemonti
Publication date
01-10-2011
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 5/2011
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-011-0216-9

Other articles of this Issue 5/2011

Current Diabetes Reports 5/2011 Go to the issue

ReviewPaper

The Past, Present, and Future of Genetic Associations in Type 1 Diabetes

ReviewPaper

Recurrence of Autoimmunity Following Pancreas Transplantation

ReviewPaper

State of the Art of Clinical Islet Transplantation and Novel Protocols of Immunosuppression

ReviewPaper

Immunoisolation of Pancreatic Islet Grafts with No Recipient’s Immunosuppression: Actual and Future Perspectives

ReviewPaper

Experimental Approaches for High-Resolution In Vivo Imaging of Islet of Langerhans Biology

Clinical Trial Report

Blockade of Leukocyte Function Antigen-1 (LFA-1) in Clinical Islet Transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits